Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gamida Cell
Biotech
Gamida accepts sale to investment firm to survive
With no luck finding a partner for Omisirge, Gamida has accepted the only way to survive is for its principal lender to acquire the company.
James Waldron
Mar 27, 2024 9:53am
Cash-strapped Gamida steps up search for strategic alternatives
Jan 29, 2024 8:41am
Gamida lays off 17%, ditches NKs to keep omidubicel going
Mar 27, 2023 9:30am
FDA extends review of Gamida Cell's approval by 3 months
Nov 22, 2022 10:55am
Gamida drops mixed bag of news on FDA submission, staffing cuts
Jan 31, 2022 9:31am
Novartis-backed Gamida hits goal in phase 3 cancer trial
May 12, 2020 8:40am